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AbstrACt
Introduction Psychotherapy is a complex intervention, 
consisting of various components and being implemented 
flexibly in consideration of individual patient’s 
characteristics. It is then of utmost importance to know 
which of the various components or combinations thereof 
are more efficacious, what their specific effect sizes 
are and which types of patients may benefit more from 
different components or their combinations.
Methods and analysis Internet-delivered cognitive–
behavioural therapy (iCBT) offers a unique opportunity to 
systematically review and quantitatively disentangle the 
efficacy of various components because, unlike face-to-
face cognitive–behavioural therapy, it allows identification 
of constituent components that are actually delivered to 
patients. We will systematically identify all randomised 
controlled trials that compared any form of iCBT against 
another form or a control intervention in the acute phase 
treatment of adult depression. We will apply component 
network meta-analysis (cNMA) to dismantle efficacy of 
individual components. We will use individual participant 
data in the cNMA to identify participant-level prognostic 
factors and effect modifiers for different components.
Ethics and dissemination The investigators of the 
primary trials will have obtained ethical approval for the 
data used in the present study and for sharing the data, if 
this was necessary, according to local requirements and 
was not covered from the initial ethic assessment. Results 
from this study will be published in peer-reviewed journals 
and presented at relevant conferences.
PrOsPErO registration number CRD42018104683.
IntrOduCtIOn 
Psychotherapy is a complex intervention, 
comprising multiple components in various 
combinations.1 Psychotherapy may be even 
more complex in practice, as its implementa-
tion is variable and flexible even in research 
settings. It is generally believed, though 
seldom empirically demonstrated,2 that effi-
cacy of psychotherapy is moderated by indi-
vidual patients’ characteristics.
Cognitive–behavioural therapy (CBT) 
is the most widely studied type of psycho-
therapy for depression. CBT, however, should 
be considered more as an umbrella term, 
because under the general label of CBT, we 
can find psychotherapies that include various 
combinations of many different components. 
Moreover, these are administered in a flexible 
manner, presumably in concordance with 
individual patient characteristics. Viewed 
from the clinicians’ and consumers’ points 
of view, it is then of utmost importance to 
determine which of the various components 
or combinations of components proposed for 
CBT are more efficacious, what their corre-
sponding effect sizes are and which types of 
patients may benefit more from different 
components or their combinations.
Apart from a few exceptions known as 
dismantling studies,3 research into CBT has 
usually studied it as a package of various 
components. The complexity of psychother-
apeutic interventions noted above at the 
levels of intervention and population applies 
strengths and limitations of this study
 ► Internet-delivered cognitive–behavioural therapy 
will allow identification of constituent components 
used in each intervention and effectively delivered 
to participants.
 ► Component network meta-analysis (cNMA) will al-
low estimation of a specific incremental effect size 
for each component.
 ► Individual participant data cNMA (IPD-cNMA) will 
allow identification of prognostic factors and effect 
modifiers for different components.
 ► IPD-cNMA, while a powerful methodology, is limited 
by the availability of individual participant data, their 
quality and their comprehensiveness.
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Table 1 List of included components and their definitions
w Waiting component Participants are aware that they can receive an active treatment after a waiting phase. Usually 
patients on a wait list do not receive any sort of treatment during the waiting phase. However, 
in some trials patients allocated to the waiting list control condition receive some non-specific 
therapeutic components such as psychological placebo, psychoeducation or treatment as 
usual while waiting. In such cases, we will consider that the ‘waiting component’ (w) is present 
and also record the interventions provided while waiting.
Sometimes publications are not clear if their control conditions allowed the intervention to 
be administered after the last assessment: in such cases, we need to check the published 
protocol, trial registries, secondary publications from the same trial and/or ask the original 
authors.
dt Conventional drug 
treatment
Treatment as usual or care as usual can denote many different conditions in the literature.21 
In this study, we focus on the presence of ‘conventional drug treatment’ and extract the data 
if it is present (drug treatment is part of the protocol treatment), allowed (we will note the 
percentage of patients on drug) or absent.
pl Placebo effect Effect of an intervention due to the patients’ belief that they are receiving some form of 
treatment.
In trials, Hawthorne effect can be considered to be always present because all the participants, 
in the intervention or the controls, will be evaluated. We therefore will drop considering 
Hawthorne effect as a component in this component NMA.
There will be a few trials that may teach skills not covered in this classification (eg, ‘expressive 
writing’ and ‘dreamwork’). We assume such miscellaneous interventions to have some placebo 
effect. However, it is possible that some of them may possess some effect beyond placebo 
effect. We will examine the robustness of our assumption by conducting a sensitivity analysis 
excluding any studies that taught such miscellaneous skills not categorisable here.
pe Psychoeducation about 
depression
Provision of information about the cause and nature of depression. Patients are taught their 
symptoms can be interpreted under a certain psychopathological model. For example, if 
cognitive distortion is cited as the cause of depression, such explanation will count towards pe 
as defined here.
Advice about lifestyle modification (eg, exercise, food and sleep hygiene (as opposed to CBT 
for insomnia)) will be regarded as form of psychoeducation.
Provision of information about depression in informational websites will count towards 
psychoeducation.
cr Cognitive restructuring This component teaches the patient to evaluate and modify their own irrational, maladaptive or 
dysfunctional thoughts using strategies such as Socratic questioning and guided imagery.
ba Behavioural activation This component aims at helping people increase potentially reinforcing experiences through 
activity scheduling and increased engagement in pleasant activities.
is Interpersonal skill 
training
Training in appropriate social behaviours. Includes assertiveness training that teaches the 
patient to stand up to their own rights by expressing their feelings and wishes in an honest and 
respectful manner that does not insult or hurt the others.
ps Problem solving This skill includes the following step-by-step approach to personal problems: defining personal 
problems, generating multiple solutions, selecting the best solution, working out a systematic 
plan for this solution and evaluating whether the solution has resolved the problem.
re Relaxation This skill is aimed at reducing general tension through induction of a relaxed body state. The 
most common technique is Jacobson’s progressive muscle relaxation or applied relaxation.
3w Third-wave components Various techniques aimed at helping patients to develop more adaptive emotional responses to 
situations, such as the ability to observe symptomatic processes without overly identifying with 
them or without reacting to them in ways that cause further distress.56 Some typical examples 
include training in mindfulness, self-compassion or acceptance.
bi Behaviour therapy for 
insomnia
This skill aims at treating chronic insomnia based on the principles of sleep restriction and 
stimulus control. It may also involve cognitive restructuring around maladaptive beliefs for 
sleep. It may also involve teaching sleep hygiene; however, sleep hygiene only would count 
towards lifestyle modification.
rp Relapse prevention Review of learnt skills and listing action plans for the foreseeable future problems based 
on the skills learnt. A mere explanation of relapse in depression will only count towards 
psychoeducation; in order to qualify for relapse prevention component, it needs more 
participation from the patient.
Continued
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to such research and adds much uncertainty to their 
analyses and interpretations.4 5 In traditional systematic 
reviews of psychotherapeutic interventions, identifica-
tion of specificity in psychotherapy has proved extremely 
difficult.6 7 Detection of differences among treatments 
and treatment components would require extremely 
large samples.3 In addition, the influence of patient-level 
characteristics on the efficacy of the interventions could 
not be adequately explored in analyses that use aggre-
gate (study-level) information, due to the risk of ecolog-
ical bias that occurs when the association at the group 
level does not reflect the underlying association at the 
individual level.8 9 Individual data, either at the level of 
a trial10 or of a meta-analysis,11 are necessary to examine 
effect modification by individual characteristics.
The recent upsurge of research in internet-delivered 
CBT (iCBT) provides a unique opportunity to system-
atically review and quantitatively disentangle the effi-
cacy of the various components of CBT. First, in iCBT, 
constituent components of CBT are easily identifiable, 
and it is guaranteed that they were made available to 
the participants, unlike in face-to-face CBT. Second, new 
hw Homework required When completion of some homework assignment is required (or explicitly encouraged 
repeatedly) before proceeding with the programme, either checked by humans or mandated 
by the programme. The homework must pertain to exercise in applying the learnt CBT or other 
skills in one’s own situations and must require some active participation from the participant. 
Simple reviewing of the materials or further reading will not be regarded as homework.
ff Initial face-to-face 
contact
Initial face-to-face human contact, such as the initial evaluation session or the initial orientation 
session, is present. In conventional drug treatment, ff is considered to be present.
ae Automated 
encouragement to 
proceed with iCBT
Provision of automated, fixed prompts/encouragements to proceed with the treatment 
programme. Such prompts should not contain any support related to the therapeutic contents.
he Human encouragement 
to proceed with iCBT
Prompts/encouragements are prepared and provided by human beings to proceed with the 
treatment programme via telephone or email. Such prompts should not contain any support 
related to the therapeutic contents.
Peer support such as discussion group will be counted towards this component.
tg Therapeutic guidance 
for iCBT
Guidance as to the contents of iCBT. Therapeutic guidance related to the treatment content 
may be provided on a scheduled basis or as-needed basis. Provision of technical support only 
is not counted towards this component.
iCBT, internet-delivered cognitive–behavioural therapy; NMA, network meta-analysis.
Table 1 Continued 
Table 2 Conceptualisation of some representative forms of iCBT or control conditions according to a component-level 
perspective
Interventions or controls Possible decompositions into components
Waiting list w (±pl±pe±dt)±ff
No treatment ±ff
Attention/psychological placebo (APP) pl±ff
Treatment as usual (TAU)* pl+dt±ff
Psychoeducation (PE)† pl+pe±rp±dt±(ae/he)±tg±ff
Relaxation therapy† pl(±pe)+re±rp±dt±(ae/he)±tg±ff±hw
Cognitive therapy† pl (±pe±re)+cr±rp±dt±(ae/he)±tg±ff±hw
Behavioural activation (BA)† pl (±pe±re)+ba±rp±dt±(ae/he)±tg±ff±hw
Problem-solving therapy† pl (±pe±re)+ps±rp±dt± (ae/he)±tg±ff±hw
Assertiveness training† pl (±pe±re)+at±rp±dt±(ae/he)±tg±ff±hw
Cognitive-behavioural therapy (CBT)† pl (±pe±re)+cr+(ba±ps±at±bi)±rp±dt±(ae/he)±tg± ff±hw
Third-wave CBT (3W)† pl (±pe±re±cr±ba±ps±at±bi)+3w±rp±dt±(ae/he)±tg±ff±hw
*TAU here must include pharmacotherapy. Watchful waiting or follow-up by community nurses will therefore be classified as APP even when 
it is ‘treatment as usual’ in some settings.
†Any of these active interventions may be provided with or without TAU.
3W, third-wave components; ae, automated encouragement to proceed with iCBT; bi, behaviour therapy for insomnia; cr, cognitive 
restructuring; dt, conventional drug treatment; ff, initial face-to-face contact; he, human encouragement to proceed with iCBT; hw, homework 
required; iCBT, internet-delivered cognitive–behavioural therapy; is, interpersonal skill training; pe, psychoeducation about depression; pl, 
placebo effect; ps, problem solving; re, relaxation; rp, relapse prevention; tg, therapeutic guidance for iCBT; w, waiting component.
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methods to analyse complex interventions and synthe-
sise their findings12 13 can then be applied to randomised 
controlled trials (RCTs) in iCBT. In this study, we will 
apply component network meta-analysis (cNMA), a 
newly developed meta-analysis method, where various 
components of different therapies can be dismantled and 
compared while taking advantage of the whole network of 
randomised evidence.14 15 We will extend existing cNMA 
models to include individual participant data (IPD) in 
the meta-analysis.16 17 This will allow us to identify and 
explore the impact of participant-level prognostic factors 
(PFs; variables that affect the disease progression equally 
for all the treatments in the network) and effect modifiers 
(EMs; variables that have an impact on the relative effects 
of interventions).
This study therefore aims to uniquely overcome the 
complexity in psychotherapy research at the levels of inter-
vention and population by identifying the more effective 
components of iCBT and by pinpointing the individual 
patient’s characteristics that modify their effects. Such 
findings will help develop more effective and more effi-
cient forms of iCBT by focusing on the best-performing 
components and facilitate personalised applications of 
iCBT, aiming to maximise the therapeutic effect while 
better matching the administered treatment to the indi-
vidual patients’ characteristics, needs and preferences.
MEthOds
The protocol follows the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses extension state-
ment for network meta-analysis,18 individual participant 
data meta-analysis19 and study protocol.20
Eligibility criteria
We will include all RCTs that compared any form of iCBT 
against another form of iCBT or a control intervention in 
the treatment of adults with depression.
We will include adult patients of both sexes aged 18 
years or older, with a primary diagnosis of depression, 
either diagnosed as unipolar major or minor depres-
sion according to operationalised diagnostic criteria 
including Diagnostic and Statistical Manual 3rd Edition 
(DSM-III), 3rd revised edition (DSM-III-R), 4th edition 
(DSM-IV), 5th edition (DSM-5), International Classifi-
cation of Diseases 10th revisioin (ICD-10) or any similar 
criteria, or judged so by elevated scores on any self-report 
depression scales. The effect of including studies without 
formal diagnosis of major depression will be tested in a 
sensitivity analysis. Inpatients as well as participants with 
bipolar depression or with psychotic depression will be 
excluded. Studies including participants with depression 
comorbid with another mental disorder will be included 
as long as their study inclusion criteria do not specifically 
include such comorbidities; however, we will exclude 
studies focusing on depression comorbid with another 
mental disorder, because in such cases, the CBT interven-
tions would usually have components that target at such 
comorbidities in addition to depression. If studies include 
patients with depression or another mental disorder, we 
will include them if and only if we can focus on partici-
pants with depression based on individual data. Studies 
focusing on depression with another physical disorder 
(eg, diabetes and parkinsonism) or in special populations 
(eg, elderly, pregnancy, mother of autistic children and 
ethnic minority) will be included; however, the effect of 
including such studies will be examined in a sensitivity 
analysis. If a minority of the participants satisfy any of the 
above exclusion criteria, we will do our best to exclude 
such participants by employing IPD: when we do not have 
IPD or cannot exclude them using IPD because details 
are not available, then we will include such studies in our 
analysis when they constitute less than 20% of the total 
population.
iCBT must be a web-based or app-based programme 
using the internet to deliver the CBT contents. Comput-
erised CBT will be included if it allows interaction 
between the programme and the individual. Telephone 
CBT will be excluded. If the use of the internet is limited 
to teleconferencing/videoconferencing, emails or text 
messaging, such programmes will also be excluded. 
When a web-based or app-based programme is used in 
the context of face-to-face sessions (so-called blended 
treatment), such programmes will be excluded because 
then the delivery of the CBT contents is no longer as 
assured as in pure iCBT. Encouragement to proceed with 
iCBT by telephone or face-to-face contact limited to an 
initial evaluation or orientation session will be allowed 
and considered to be a component of iCBT programme. 
Studies will be excluded if the iCBT programme allows 
participants to choose among the available components 
because such studies will not answer our clinical question.
The control conditions of interest will include the 
waiting list control, no treatment control, attention/
psychological placebo control and treatment as usual. 
Different studies call different conditions as treatment 
as usual.21 In this cNMA study, treatment as usual must 
include pharmacotherapy; watchful waiting or follow-up 
by community nurses will be classified as attention/
psychological placebo even when it is ‘treatment as usual’ 
in some settings. Pill placebo control will not be included 
in the present network as it is not decomposable into the 
components of our interest.
This study focuses on the acute phase treatment of the 
above-defined depression. The intervention can be of 
any duration; however, the influence of duration will be 
examined in a meta-regression.
We conceptualise CBT broadly as a psychotherapy 
involving any one of the following cognitive or behavioural 
skills’ training. Table 1 presents the different components 
of interest and their definitions. We will include all inter-
vention or control conditions as long as they could be 
regarded as a combination of these components. Phar-
macological coadministration will be allowed so long as 
there are no systematic differences in drug administra-
tion between study arms, and its presence will be denoted 
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by dt (for definition see table 1). Table 2 provides how 
various forms of iCBT can be conceptualised from the 
component perspective.
study identification and selection
We will use an existing database of psychological treat-
ments for depression that is updated annually through 
comprehensive literature searches in the bibliographic 
databases of PubMed, PsycINFO, Embase and the 
Cochrane Library.22 The search strings use a combination 
of index and free terms of psychological treatments and 
depression.
Two independent researchers will check this database 
for relevant studies according to the eligibility criteria. 
Any disagreement will be resolved by discussion and, 
where necessary, in consultation with a third reviewer.
A further literature search will be conducted for studies 
published since the last update of the database in PubMed 
and the Cochrane Library. In addition, we will also check 
the primary studies from recent meta-analyses of internet 
treatments for depression to ensure that no published 
studies will be missed. We will also ask the primary authors 
of the eligible studies if they are aware of any other study 
that has been conducted in the examined field.
data collection and integrity checks
Authors of the eligible studies will be contacted and 
requested to contribute their individual-level data. The 
corresponding author will be contacted first; if unreach-
able, a follow-up email will be sent to the senior author 
of the study. Reminders will be sent after 2 weeks and if 
necessary after 4 weeks. If no response is received after 
additional 4 weeks, this trial will be classified as ‘IPD 
unavailable’ and will be included in the analyses at the 
aggregate data level.
Authors will be asked to provide the individual-level 
raw data for their primary depression measures at base-
line and at end of the acute phase treatment defined by 
the original study authors, as well as other potentially 
important covariates (PFs and EMs of treatment outcome; 
see section below).
After collecting all primary individual-level data, two 
independent reviewers will cross-examine the obtained 
data against the summary statistics (numbers and percent-
ages or means and SDs) of the baseline demographic and 
clinical variables as reported in the publications of each 
study. In case the numbers do not match, we will contact 
the authors of the trials for clarification.
Identification of components
Two independent reviewers will determine the classifica-
tion of all identified arms and their constituent compo-
nents according to the definitions in tables 1 and 2, based 
on all available information including the publications, 
the trialled iCBT programmes and inquiry with the orig-
inal investigators. Any disagreement will be solved by the 
two reviewers and, where necessary, in consultation with a 
third member of the review team.
Outcome measures
Our primary outcome is:
1. Depression severity as measured on a continuous 
scale for depression at the end of the acute phase 
treatment. We will include change in scores from pre-
treatment to post-treatment on any validated depres-
sion outcome measure, such as the Beck Depression 
Inventory, Beck Depression Inventory-II, Center of 
Epidemiological Studies Depression Scale, Patient 
Health Questionnaire-9 or Hamilton Rating Scale for 
Depression. If a study uses more than one depression 
measure, preference will be given to the measure re-
ported by the majority of the included studies. In case 
a study reports two or more outcome measures, none 
of which are used by the rest of the included studies, 
preference will be given to the measure listed as pri-
mary in this study. If the studies use different outcome 
measures, they will be converted into the most com-
monly used scale using the established conversion 
algorithms.23 24 If this approach cannot cover a sub-
stantial proportion of the obtained data, scale scores 
will be standardised (transformed into z-scores) to cre-
ate a common metric for depression severity.25–27
We will also examine the following two secondary 
outcome measures.
2. Dropouts from the end-of treatment assessment for 
any reason, as a proxy measure of treatment accept-
ability.
3. Dropouts from the treatment, defined as completing 
less than 80% of the contents of the programme. If the 
original authors used a different threshold/definition 
for ‘completion’ of the programme, we will use their 
definition.
PFs and EMs of treatment outcome
In this study, we will start from a wide range of patient-
level variables and explore their role as either PFs or 
EMs. We will initially select candidate covariates based on 
previous literature findings and the availability of these 
variables in the included studies. The following is the list 
of candidate variables based on the published literature.28
Demographics
1. Sex.
2. Age.29
Life and social history
3. Childhood maltreatment.30
4. Education.31
5. Employment.2 32
6. Marital status.2 32 33
7. Recent life events and difficulties.2 32
8. Social adjustment/function.34
History of present illness
9. Age at onset.35
10. Duration of current episode.29
11. No of previous episodes.31 36
12. Prior treatment with antidepressants.2
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13. Prior treatment with psychotherapies.
Present illness: symptomatology
14. Baseline severity.37–39
15. Baseline psychomotor symptoms.34 40
16. Baseline anxiety symptoms.40 41
17. Baseline somatic anxiety.34
18. Comorbid personality disorder.2
19. Comorbid alcohol or substance use/abuse.40
The following study-level characteristics will also be 
examined as PF or EM.
Study characteristics
20. Duration of intervention.42
21. Presence of inactive control condition.43
It can be expected that different studies use different 
scales or different categorisations to measure the same 
or similar constructs. Some measures (eg, social adjust-
ment and baseline anxiety) may be standardised to arrive 
at a common metric; others may need be dichotomised 
(eg, employment status, marital status) to harmonise the 
covariates in the analyses.
risk of bias assessment in individual studies
Two independent raters will assess the risk of bias in the 
included studies using the tool described in the Cochrane 
Collaboration Handbook44 as being at high risk of bias, 
low risk of bias or unclear risk of bias in the following 
domains: generation of allocation sequence, allocation 
concealment, blinding of study personnel and partic-
ipants, blinding of outcome assessor, attrition, selective 
outcome reporting and other domains. Disagreements 
between the two independent assessors will be solved 
through discussion; when there still remains doubt, we 
will go back to the original authors for clarification.
Note that blinding of study personnel and participants 
is usually impossible in psychotherapy research; however, 
in studies of iCBT, it may be at least theoretically feasible 
if alternative active treatments are provided simply as 
‘active treatments’. Note also that attrition bias will be 
evaluated in the case of studies with individual-level data, 
not according to the published report, but according to 
the provided dataset after missing data are imputed as 
per the statistical methods below. Some studies may still 
be rated at high risk of bias after imputation if large and 
unbalanced dropouts exist in the provided raw data. In 
the case of studies without individual data, attrition bias 
will be rated according to the publication.
In the above risk of bias assessment, we chose not to eval-
uate treatment fidelity as it will not be an issue with iCBT, 
which is fully structured. We also chose not to evaluate 
allegiance as its measurement is still controverted and 
will be especially difficult to measure in the comparisons 
against control conditions45 and may be less important in 
high-quality studies.46
Patient and public involvement
There was no patient or public involvement in the devel-
opment of this manuscript.
synthesis methods
We will start by performing an aggregated data network 
meta-analysis (NMA) on the treatment level to gain a first 
insight of the relative treatment effects.47 We will do this 
analysis both with and without trials for whom we do not 
have IPD.
Then we will continue to our main analysis. This will 
be done in two steps. In the first step, we will perform 
a variable selection procedure to decide which of the 
candidate covariates to include in the evidence synthesis 
model of the second step. To this end, we will fit a penal-
ised linear regression model with an elastic net penalty48 
to our primary outcome (continuous efficacy). We will 
explore all candidate covariates as well as their interac-
tions with the components, aiming to identify the most 
important patient characteristics in terms of both prog-
nosis and effect modification. Aiming to facilitate conver-
gence of the models and to help the interpretation of 
the results of the second step, all continuous covariates 
will be standardised, that is, by subtracting the mean 
and dividing by the corresponding SD. The output of 
this first step of the analysis will be a list of PFs and EMs. 
Note that different EMs may be associated with different 
components, for example, patient age may be found to 
strongly interact with cognitive restructuring but not with 
behavioural activation.
At the second step, we will fit a one-stage IPD-NMA 
model.16 17 Let us assume that study  j   compares two inter-
ventions  T1  and  T2 , where  T1  comprises components  c1  and 
 c2  and  T2  comprises components  c3 and c4 . Let us assume 
that patient  i  in this study had an observed outcome  yij  . 
Let us also assume that for this patient we have the corre-
sponding PFs in the form of a vector  PFij  . Similarly, let 
us assume that the EMs for this patient, for each compo-
nent, are in vectors  EM
(
c1
)
ij  ,  EM
(
c2
)
ij  ,  EM
(
c3
)
ij   and  EM
(
c4
)
ij  . 
The model can now be written as follows:
  
yij ∼ N
(
zij, s
2
j
)
  
  
zij =
uj + βPFij + γ
(
c1
)
EM
(
c1
)
ij + γ
(
c2
)
EM
(
c2
)
ij , if treatij = T1 =
(
c1 + c2
)
uj + βPFij + γ
(
c3
)
EM
(
c3
)
ij + γ
(
c4
)
EM
(
c4
)
ij + δj, if treatij = T2 =
(
c3 + c4
)
  
In this expression,  β  is the vector of regression coeffi-
cients associated to PFs.  s
2
j   is the study-specific variance 
of  yij  .  γ
(
cX
)
  is the vector of regression coefficients for 
effect modification (component–covariate interaction), 
for componentX  . The ‘baseline’ effect,  uj  , will be assumed 
exchangeable across studies, that is,  uj ∼ N
(
mu,σ2u
)
.δj   is 
the study-specific estimate of relative effect for  T2  versus 
 T1 , at the zero values of the (possibly standardised) EMs, 
that is, when all  EM = 0 . We will assume that  δj ∼ N
(
µj, τ2
)
 , where τ  denotes the random effects SD in the network. 
We will assume τ  to be common for all treatment 
comparisons in the network. Finally,  µj   will be expressed 
as a linear combination of the effects of the compo-
nents, for example, for this particular example we will 
set  µj = d3 + d4 − d2 − d1 . This model assumes additivity 
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of treatment effects (Welton et al14). In order to include 
in our analysis patients with missing values for one or 
more of the covariates (both PFs and EMs), we will use 
a study-specific imputation scheme. For example, if for 
patient  i  in study  j   there is no information regarding 
age, we will stochastically impute it by drawing from a 
study-specific distribution, that is, 
 
ageij ∼ N
( −
agej, s
2
age,j
)
 
. 
Here  
−
agej   denotes the mean age of patients in this study 
and  s
2
age,j   the corresponding variance.
For the secondary outcome ‘dropout from end-of-treat-
ment assessment’, we will use a binomial likelihood for 
the observed data. We will synthesise data on the OR scale. 
The rest of the model will be as for the primary outcome.
For the secondary outcome ‘dropout from the treat-
ment’, we will use a different modelling approach. This is 
because, by definition, for the inactive control conditions, 
treatment dropout is not observed. This implies that in 
studies with inactive controls, we cannot infer about rela-
tive effects. Such studies are expected to represent the 
vast majority of all eligible studies. Thus, for the analysis 
of this outcome, we will synthesise absolute treatment 
effects. We will model the probability of dropout for each 
active treatment, using a generalised linear model with a 
binomial likelihood
We will implement the variable-selection proce-
dure of our analysis (step one) in R,49 using the glmnet 
package.50 The variable-selection procedure will only be 
performed for the primary outcome. We will implement 
the evidence-synthesis part (step 2) in OpenBUGS.51
Limitations of the proposed statistical model
The basic model assumes additivity of components and 
does not take account of possible interactions among 
components, that is, when some components may be 
particularly effective or ineffective in combination with 
some other components. The dataset will likely lack statis-
tical power to test for such interactions. However, for 
components that are well represented in the network (ie, 
those which have been studied in many trials involving 
many participants), we will run exploratory analyses of 
some representative interactions.
The proposed model cannot discern the effect of the 
ordering of the components, but we expect that we will 
not have enough relevant data from the studies to explore 
this effect. If enough data become available, we will 
modify our model to explore the ordering effect among 
the most well-represented components of the network.
heterogeneity and inconsistency
We will measure heterogeneity in the included studies 
by estimating a common heterogeneity parameter τ
 , as described in the previous section. We will compare 
this estimate with its empirical distribution,52 53 for the 
dropout outcome. For the continuous outcome, we will 
compare τ  with an empirical distribution (Rhodes et al52) 
only if we use standardised scores (see section Outcome 
measures).
We expect that the inclusion of the covariates in the 
model will lower the observed inconsistency, that is, by 
explaining some of the observed differences between the 
studies. In order to assess this, we will also fit a model 
without patient covariates and report any changes in τ  .
We will assess inconsistency in the network at the treat-
ment level by estimating the difference between direct 
and indirect evidence. For this, we will use the design-by-
treatment inconsistency model (Higgins et al44). We will 
then also check inconsistency at the component level and 
report on any important differences.
data availability bias
As discussed above, we anticipate that for at least some 
of the identified trials, we might not be able to obtain 
IPD. If studies providing IPD are systematically different 
from studies not providing IPD, there may be doubts 
regarding the validity of our findings. We will formally 
assess the agreement between these two sets of trials by 
analysing them separately and subsequently comparing 
the corresponding results. We will report any important 
discrepancies, and we will take them into consideration 
when we evaluate the quality of the evidence provided by 
our analysis.
Publication bias
We will first examine small study effects by visually 
inspecting the contour-enhanced funnel plots of pair-
wise meta-analyses for efficacy when 10 or more studies 
per comparison are available. We will test for small study 
effects using Egger’s test for the continuous outcome.54
sensitivity analyses
The following five sensitivity analyses will be conducted 
for the primary outcome.
i. We will examine the impact of studies without formal 
diagnosis of depression by excluding such studies 
from the analyses.
ii. We will examine the impact of studies focusing on 
patients with depression and a physical disorder by 
excluding such studies from the analyses.
iii. We will examine the impact of miscellaneous skills 
not covered under any category in our classification 
in table 1 by excluding studies that included such 
skills.
iv. We will run a sensitivity analysis by limiting to studies 
where at least 60% of the participants have complet-
ed at least 80% of the programme in order to exclude 
the influence of trials where the completion rate may 
have been particularly low due to some external cir-
cumstances that are not inherent to the components 
themselves.
v. Our main analyses regarding depression severity will 
only use information from patients for whom the 
outcome was reported. This corresponds to a ‘miss-
ing completely at random (MCAR)’ assumption.55 
In this sensitivity analysis, we will explore a ‘missing 
not at random’ scenario, where we will assume that 
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the probability of dropping out from assessment is af-
fected by the (unobserved) depression severity. More 
specifically, we will use a selection model described by 
Debray et al,16 where patients with worse outcomes are 
more likely to drop out. We will perform this sensitivi-
ty analysis only if the dropout rates are high (>50%).
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